Derma Sciences to Participate in Canaccord Genuity Medical Technologies and Diagnostics Forum

PRINCETON, N.J.--()--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that Edward J. Quilty, the Company’s chairman and chief executive officer will participate in a “Fireside Chat” at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 20th at 8:30 a.m. ET. The conference will be held at the Westin Grand Central in New York City

To listen to the discussion investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com or at http://www.wsw.com/webcast/canaccord16. An archived audio of the discussion will also be available on Derma Sciences’ website for 90 days.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014. AMNIOEXCEL has been launched to customers and the Veterans Administration recently has included the product in its Federal Supply Schedule V797P-2000D. Derma Sciences’ MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, a patented active pharmaceutical ingredient (API) which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. DSC127 is also in preclinical testing for scar prevention/reduction and is part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The Company also offers a full product line of traditional dressings.

For more information please visit www.dermasciences.com.

Contacts

Derma Sciences, Inc.
John Yetter, 609-514-4744
Chief Financial Officer
jyetter@dermasciences.com
or
Investors
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
or
Media
Spectrum Science Communications
Leticia Diaz, 202-955-6222
ldiaz@spectrumscience.com

Derma Sciences, Inc.